Open AccessAntimalarial chloroquine indicated for viral infections: myth ou hope?
Author(s) -
Guilherme Marinho Sampaio,
Gabriel Henrique Queiroz Oliveira,
Hadassa Fonsêca Silva,
Alice Pinho André Gomes Morais,
Jatiacynan Andrade de Souza,
William José Lopes de Freitas,
Paulo Maurício Reis de Melo Júnior,
Sandra Sayão Maia,
João Henrique Santos Silva,
Juliana Mariano Carvalho Azevedo,
Rodolfo Scavuzzi Carneiro Cunha,
Sheyla Priscila Madeira Melo,
Luisa Manuela Pomba Samba,
Caroline Isabele Félix Muniz,
Marcela Nogueira dos Santos,
Luciano Barreto Silva
Publication year - 2021
Publication title -
research, society and development
Language(s) - English
Resource type - Journals
ISSN - 2525-3409
DOI - 10.33448/rsd-v10i10.18220
Subject(s) - azithromycin , chloroquine , hydroxychloroquine , medicine , intensive care medicine , torsades de pointes , covid-19 , pandemic , qt interval , malaria , antibiotics , immunology , infectious disease (medical specialty) , disease , microbiology and biotechnology , biology
Aim: this article describes the use of chloroquine as an antimalarial agent with potential antivirotic indications for COVID-19 infections. Methods: On line searches and gray literature have been used in the construction of this articles, whose database include PUBMED Central, BVS/BIREME, Web of Science, Science Direct, Higher Level Personnel Improvement Coordinator (CAPES), Periodic Door (Portal de Periódicos da CAPES, The Cochrane Library and PROSPERO). Results: chloroquine and hydroxychloroquine has shown appropriate clinical reports when associated with the antibiotic Azithromycin. It has been authorized for the clinical treatment of grave acute forms of COVID infections by countries like Brazil and USA. Conclusions: Chloroquine seems to have potential antivirotic properties that may be useful in the treatment of the grave acute forms of COVID-19 associated with Azithromycin. Nevertheless, Its indication must include ECG monitoring due to the risk of cardiac QT prolongation able to cause sudden deaths.